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Favipiravir, a viral RNA-dependent RNA polymerase inhibitor, has recently been approved in Japan for
inﬂuenza pandemic preparedness. Here, we conducted a cell-based screening system to evaluate the
susceptibility of inﬂuenza viruses to favipiravir. In this assay, the antiviral activity of favipiravir is
determined by inhibition of virus-induced cytopathic effect, which can be measured by using a colori-
metric cell proliferation assay. To demonstrate the robustness of the assay, we compared the favipiravir
susceptibilities of neuraminidase (NA) inhibitor-resistant inﬂuenza A(H1N1)pdm09, A(H3N2), A(H7N9)
and B viruses and their sensitive counterparts. No signiﬁcant differences in the favipiravir susceptibilities
were found between NA inhibitor-resistant and sensitive viruses. We, then, examined the antiviral
susceptibility of 57 pairs of inﬂuenza viruses isolated from patients pre- and post-administration of
favipiravir in phase 3 clinical trials. We found that there were no viruses with statistically signiﬁcant
reduced susceptibility to favipiravir or NA inhibitors, although two of 20 paired A(H1N1)pdm09, one of
17 paired A(H3N2) and one of 20 paired B viruses possessed amino acid substitutions in the RNA-
dependent RNA polymerase subunits, PB1, PB2 and PA, after favipiravir administration. This is the ﬁrst
report on the antiviral susceptibility of inﬂuenza viruses isolated from patients after favipiravir
treatment.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
In Japan, four neuraminidase (NA) inhibitors, oseltamivir,
zanamivir, peramivir and laninamivir, are approved for therapeutic
or prophylactic treatment against inﬂuenza virus infection.
Because they are prescribed at the highest frequency in the world,
we have been conducting nationwide monitoring for the antiviral
susceptibility of inﬂuenza viruses since 1999 (Monto et al., 2006;
Takashita et al., 2013; Tashiro et al., 2009; Ujike et al., 2010,
2011). After the (H1N1)2009 pandemic started, the detection
rate of NA inhibitor-resistant A(H1N1)pdm09 viruses was low
(approximately 1%) and no resistant A(H3N2) and B viruses werer B.V. This is an open access articledetected in Japan. However, between November 2013 and
February 2014, a large cluster of mutant A(H1N1)pdm09 viruses
cross-resistant to oseltamivir and peramivir with an H275Y sub-
stitution (N1 numbering) in the NA protein emerged in Hokkaido,
Japan (Takashita et al., 2014, 2015a). The detection rate for this
resistant virus reached 29% in this area. Our previous report sug-
gested that the novel variant retained replication and transmission
capability to spread among humans, due to the permissive sub-
stitutions V241I and N369K (N1 numbering) in the NA protein
(Takashita et al., 2015a). Furthermore, signiﬁcant numbers of
oseltamivir and peramivir cross-resistant A(H1N1)pdm09 viruses
were also detected in China and the United States (Huang et al.,
2015; Okomo-Adhiambo et al., 2015; Takashita et al., 2015b).
Therefore, the surveillance of antiviral-resistant inﬂuenza viruses
is important to protect public health and aid in clinical
management.under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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pyrazinecarboxamide) inhibits the RNA-dependent RNA polymer-
ase of inﬂuenza viruses (Furuta et al., 2005). Favipiravir is converted
to 4-ribofuranosyl-5-triphosphate metabolite by intracellular en-
zymes and may be misincorporated into the nascent RNA strand as
an adenosine and a guanosine analog, preventing incorporation of
natural ATP and GTP for viral RNA synthesis (Jin et al., 2013;
Sangawa et al., 2013; Furuta et al., 2013). Favipiravir is active
against a broad range of inﬂuenza A, B and C viruses, including
highly pathogenic avian A(H5N1) and novel avian A(H7N9) viruses
(Kiso et al., 2010; Watanabe et al., 2013) and has antiviral activity
against inﬂuenza viruses resistant to NA inhibitors or adamantane
(Sleeman et al., 2010; Watanabe et al., 2013). Favipiravir also has
broad-spectrum activities against various other RNA viruses, such
as arenaviridae, bunyaviridae, caliciviridae, ﬂaviviridae, picorna-
viridae, paramyxoviridae and togaviridae (Delang et al., 2014;
Furuta et al., 2002, 2009, 2013; Rocha-Pereira et al., 2014).
Recently, the efﬁcacy of favipiravir against Ebola virus in vitro and
in vivo was also reported (Oestereich et al., 2014; Smither et al.,
2014). Subsequently, a clinical trial named the JIKI study, which is
testing the efﬁcacy of favipiravir in reducing mortality associated
with Ebola virus infections in Guinea, is ongoing as of April 2015
(Kupferschmidt and Cohen, 2015). In Japan, favipiravir was
approved for inﬂuenza pandemic preparedness on March 24, 2014
(http://www.toyama-chemical.co.jp/eng/news/news140324e.
html). Therefore, there is a need to develop convenient assays that
monitor favipiravir susceptibility of inﬂuenza viruses. The suscep-
tibility of inﬂuenza viruses to favipiravir has been determined by
using plaque reduction, yield reduction or focus inhibition assays in
the previous reports (Furuta et al., 2002; Sidwell et al., 2007;
Sleeman et al., 2010). Here, we conducted a cell-based screening
system to evaluate favipiravir susceptibility, that is, a colorimetric
cytopathic effect (CPE) reduction assay. Using our approach, we
examined the susceptibility of a panel of NA inhibitor-resistant
viruses and their sensitive counterparts to favipiravir. Further-
more, the antiviral susceptibility of 57 pairs of inﬂuenza A(H1N1)
pdm09, A(H3N2) and B viruses isolated from patients pre- and
post-administration of favipiravir in phase 3 clinical trials were
determined.
2. Materials and methods
2.1. Viruses
A panel of NA inhibitor-resistant viruses and their sensitive
counterparts was used in this study (Table 1). A/Chiba/1017/2009
and A/Chiba/1016/2009 were isolated in Japan and used as refer-
ence H275Y mutant and 275H wild-type A(H1N1)pdm09 viruses,
respectively (Ujike et al., 2011). A/Fukui/45/2004 and A/Fukui/20/
2004 were kindly provided by the ISIRV Antiviral Group (http://
www.isirv.org/site/index.php/reference-panel) and used as refer-
ence E119V mutant and 119E wild-type A(H3N2) viruses, respec-
tively (World Health Organization, 2012a). A/Kagoshima/2/2012
and A/Kagoshima/4/2012 were used as reference R292K mutant
and 292R wild-type A(H3N2) viruses, respectively. These A/
Kagoshima strains were isolated from clinical specimens distrib-
uted by Kagoshima Prefectural Institute for Environmental
Research and Public Health, Japan. Plaque puriﬁed A/Shanghai/1/
2013-292K and A/Shanghai/1/2013-292R were used as reference
R292K mutant and 292R wild-type A(H7N9) viruses, respectively
(Watanabe et al., 2013). A/Shanghai/1/2013 was kindly provided by
Dr. Yuelong Shu (Chinese Center for Disease Control and Preven-
tion, China). All experiments with A(H7N9) viruses were carried
out in approved biosafety level 3 (BSL-3) containment laboratories.
Plaque puriﬁed B/Perth/211/2001-197E and B/Perth/211/2001-197D were kindly provided by the ISIRV Antiviral Group and used
as reference D197E mutant and 197D wild-type B/Yamagata-line-
age viruses, respectively (World Health Organization, 2012a). All
viruses were propagated in MDCK (NBL-2) cells. Amino acid posi-
tion numbering is A subtype and B type speciﬁc.
Nasal swabs were obtained from adult patients positive for
inﬂuenza virus in phase 3 clinical trials of favipiravir between
October 2009 andOctober2010according to theprotocols JP312 and
JP313 meeting IRB approval by each study site (http://www.
clinicaltrials.jp/user/showCteDetailE.jsp?japicId¼JapicCTI-
090934). Subjectswere administered favipiravir (1200/400mg for 1
dayþ 400mg bid for 4 days) and the specimens were collected pre-
and1or2dayspost-administrationof favipiravir. InﬂuenzaA(H1N1)
pdm09, A(H3N2) and B viruseswere isolated from the specimens by
using MDCK (NBL-2) cells by Toyama Chemical Co., Ltd. (Toyama,
Japan). Twenty pairs of A(H1N1)pdm09 and B viruses and 17 pairs of
A(H3N2) viruses were sent to the National Institute of Infectious
Diseases without the corresponding patient records and were
propagated in MDCK (NBL-2) cells for further analysis. Since most B
viruses isolated were B/Victoria-lineage, 19 of 20 pairs of B viruses
were B/Victoria-lineage and one pair was B/Yamagata-lineage.
2.2. Antiviral compounds
Oseltamivir carboxylate and zanamivir were purchased from
Sequoia Research Products (Pangbourne, United Kingdom). Favi-
piravir, oseltamivir carboxylate and zanamivir were dissolved in
distilled water as 5 mM stocks and stored in aliquots at 20 C.
2.3. Colorimetric CPE reduction assay
Antiviral activity of favipiravir was determined by inhibition of
virus-induced CPE. A tetrazolium compound [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt; MTS] is converted by
viable cells into a colored formazan product that is soluble in cell
culture medium (Cory et al., 1991). The quantity of formazan
product is proportional to the number of viable cells (Cory et al.,
1991). We used a single solution consisting of the MTS tetrazo-
lium compound and an electron coupling reagent (phenazine
ethosulfate; PES) in the CellTiter 96 AQueous One Solution Reagent
(Promega Corporation, Madison, WI, USA) for homogeneous
screening assay to monitor the amount of CPE.
Conﬂuent monolayers of MDCK (NBL-2) cells in 96-well tissue
culture plates were inoculated with 50 ml of viruses. A multiplicity
of infection (MOI) of 0.01 50% tissue culture infective dose (TCID50)/
cell was the most suitable for this assay, although we tested serial
dilutions (MOI of 0.0001e10) of viruses. Virus adsorption was car-
ried out in the absence of favipiravir for 1 h at 37 C in a 5% CO2
incubator and then 50 ml of culture medium containing serial di-
lutions (0.05e1000 mM) of favipiravir was added to each well in
triplicate. The cytotoxicity of favipiravir was evaluated in parallel by
using uninfected MDCK (NBL-2) cells and favipiravir showed no
cytotoxicity in this concentration range (data not shown). We
assessed the susceptibility to favipiravir when maximum CPE was
observed in control cells containing virus with no favipiravir under
a microscope, i.e., on days 3e5 post-infection, depending on the
virus strain. To measure the extent of CPE, 20 ml of CellTiter 96
AQueous One Solution Reagentwas added to eachwell and the cells
were incubated for 2 h at 37 C in a 5% CO2 incubator. Absorbance
was then measured at 490 nm with a reference wavelength of
650 nm. The susceptibilities of viruses to favipiravir were expressed
as the 50% effective concentration (EC50). The EC50 values were
calculated by using GraphPad Prism version 5.04 for Windows
(GraphPad Software, San Diego, CA, USA).
Table 1
The panel of inﬂuenza viruses used in this study.
Subtype Isolate name Amino acid substitution ina: Susceptibility to:
NA M2 Oseltamivirb Zanamivirb Peramivirb Laninamivirb Adamantanec Favipiravir
EC50 [mM]d IC50 [mM]e
A(H1N1)
pdm09
A/Chiba/1017/2009 H275Y S31N HRI NI HRI NI Resistant 3.66 ± 0.04 0.43 ± 0.09
A/Chiba/1016/2009 275H (Wild-type) S31N NI NI NI NI Resistant 3.55 ± 0.06 0.35 ± 0.16
A(H3N2) A/Fukui/45/2004 E119V 31S (Wild-type) RI NI NI NI Sensitive 9.83 ± 0.03 0.16 ± 0.07
A/Fukui/20/2004 119E (Wild-type) 31S (Wild-type) NI NI NI NI Sensitive 12.17 ± 0.08 0.14 ± 0.05
A/Kagoshima/2/2012 R292K S31N HRI RI HRI NI Resistant 12.05 ± 0.05 0.22 ± 0.08
A/Kagoshima/4/2012 292R (Wild-type) S31N NI NI NI NI Resistant 16.17 ± 0.04 0.22 ± 0.01
A(H7N9) A/Shanghai/1/2013-292K R292K S31N HRI RI HRI RI Resistant 38.72 ± 0.13 df
A/Shanghai/1/2013-292R 292R (Wild-type) S31N NI NI NI NI Resistant 20.65 ± 0.03 e
B B/Perth/211/2001-197E D197E dg RI RI RI NI dg 2.92 ± 0.05 0.45 ± 0.02
B/Perth/211/2001-197D 197D (Wild-type) e NI NI NI NI e 3.28 ± 0.04 0.99 ± 0.01
a Amino acid position numbering is A subtype and B type speciﬁc.
b HRI ¼ highly reduced inhibition, RI ¼ reduced inhibition, NI ¼ normal inhibition.
c Adamantane resistance is associated with M2 S31N amino acid substitution.
d EC50 values were determined by the use of the colorimetric cytopathic effect reduction assay. The values are presented as the mean ± SD of at least three reactions.
e IC50 values were determined by the use of the plaque reduction assay. The values are presented as the mean ± SD of six reactions.
f Not tested.
g Not applicable.
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Antiviral activity of favipiravir was also determined by using a
conventional plaque reduction assay as previously described
(Furuta et al., 2002). Conﬂuent monolayers of MDCK (NBL-2) cells
in 6-well tissue culture plates were inoculated with 50 PFU/well of
viruses. Virus adsorption was carried out in the absence of favi-
piravir for 1 h at 37 C in a 5% CO2 incubator and then the inoculum
was removed. A 0.8% agarose in culture medium containing serial
dilutions (0.05e1000 mM) of favipiravir was added to each well in
triplicate. The cells were incubated for 3 days and the plaque
numbers were counted. The 50% inhibitory concentration (IC50)
values were calculated by using GraphPad Prism.
2.5. NA inhibition assay
The susceptibilities of the viruses to NA inhibitors, oseltamivir
and zanamivir, were determined by using a chemiluminescent NA
inhibition assay with the NA-XTD Inﬂuenza Neuraminidase Assay
Kit (Applied Biosystems, Foster City, CA, USA). The IC50 values were
calculated by using GraphPad Prism. To interpret NA inhibitor
susceptibility, we used the World Health Organization criteria,
which are based on the fold-change in IC50 compared to themedian
for viruses from the same type/subtype/lineage showing normal
inhibition (World Health Organization, 2012b). Reduced inhibition
is deﬁned as a 10- to 100-fold increase in IC50 for inﬂuenza A vi-
ruses, or a 5- to 50-fold increase in IC50 for inﬂuenza B viruses.
Viruses showing highly reduced inhibition are inﬂuenza A viruses
with >100-fold increase in IC50 or inﬂuenza B viruses with >50-fold
increase in IC50 (World Health Organization, 2012b).
2.6. Sanger sequencing
Viral RNAwas prepared from isolates by using the QIAamp viral
RNA kit (Qiagen, Düsseldorf, Germany). The full-length polymerase
basic subunit 1 (PB1), polymerase basic subunit 2 (PB2), polymer-
ase acidic subunit (PA) and nucleoprotein (NP) genes were ampli-
ﬁed fromviral RNA by using SuperScript III One-step RT-PCR system
with Platinum Taq (Invitrogen, Carlsbad, CA). Nucleotide sequences
were determined by using the BigDye terminator v3.1 cycle
sequencing kit (Applied Biosystems) with Applied Biosystems 3730
DNA Analyzer. Primer sequences are available upon request.2.7. Deep sequencing
A cDNA library was prepared from viral RNA by using NEBNext
Ultra RNA Library Prep Kit for Illumina and NEBNext Singleplex
Oligos for Illumina (New England Biolabs, Ipswich, MA, USA), fol-
lowed by puriﬁcation by using Agencourt AMPure XP (Beckman
Coulter, Brea, CA, USA) according to the manufacturer’s instruction.
The library was sequenced by using MiSeq Reagent Kits v2 with
MiSeq (Illumina, San Diego, CA, USA). Sequence reads were aligned
to the reference sequence of A/California/07/2009 (H1N1)pdm09
by using CLC Genomics Workbench 8 (CLC bio, Aarhus, Denmark).
The threshold of 10%was used for the detection of single nucleotide
polymorphisms.
2.8. Mini-genome assay
Luciferase-based mini-genome assay was performed as previ-
ously described (Octaviani et al., 2010). Expression plasmids for
PB1, PB2, PA and NP proteins were constructed from those of A/
California/04/2009(H1N1)pdm09 (Octaviani et al., 2010). The
plasmid pPolINP(0)luc2(0) (20 ng), which expresses a ﬁreﬂy lucif-
erase gene between the noncoding regions of the NP gene, was
cotransfected into 293T cells in 96-well plates, along with the
protein expression plasmids for PB1, PB2, PA and NP (20 ng) and
pRL-null renilla luciferase control reporter vector (4 ng; Promega
Corporation), by using the TransIT-293 Transfection Reagent (Mirus
Bio, Madison, WI, USA) (3 ml/mg of plasmid). To determine the IC50
values of the polymerase complexes, serial dilutions
(0.05e1000 mM) of favipiravir were added to the cells. The lucif-
erase activity in the transfected cells was measured by using the
Dual-Glo Luciferase Assay System (Promega Corporation) at 24 h
post-transfection. The relative ﬁreﬂy luciferase activity, normalized
to the renilla luciferase activity, was calculated. The IC50 values
were calculated by using GraphPad Prism.
2.9. Statistical analysis
Statistical analyses were performed using GraphPad Prism.
Grubb’s test was used to detect signiﬁcant outliers. Statistically
signiﬁcant differences between groups were determined by using
Paired t-test and Fisher’s exact test. P values of <0.05 were
considered statistically signiﬁcant.
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3.1. Favipiravir susceptibility of NA inhibitor-resistant inﬂuenza
viruses
Using the CPE reduction assay, we compared the favipiravir
susceptibilities of NA inhibitor-resistant viruses and their sensitive
counterparts. A panel of representative human inﬂuenza A(H1N1)
pdm09, A(H3N2), A(H7N9) and B viruses was tested. The A(H1N1)
pdm09-H275Y, A(H3N2)-E119V or -R292K, A(H7N9)-R292K and
inﬂuenza B-D197E viruses exhibited highly reduced inhibition or
reduced inhibition against at least one of the four NA inhibitors and
most of them were also resistant to adamantane, which blocks the
M2 ion channel (Table 1). Since no favipiravir-resistant inﬂuenza
viruses have been reported to date, positive controls for resistance
to this drug do not exist.
The EC50 values of the NA inhibitor-resistant and wild-type vi-
ruses to favipiravir were determined by using the CPE reduction
assay (Table 1). The IC50 values of the same viruses were deter-
mined by using the conventional plaque reduction assay (Table 1).
Not only the number but also the size of plaques decreased as
favipiravir concentration increased. No signiﬁcant differences in
the favipiravir susceptibilities were found between NA inhibitor-
resistant and wild-type viruses by either assay, consistent with a
previous study (Sleeman et al., 2010).3.2. Favipiravir susceptibility of inﬂuenza viruses isolated from
patients pre- and post-administration of favipiravir
To examine the favipiravir susceptibility of inﬂuenza viruses
after favipiravir administration, we determined the EC50 values of
the viruses isolated before or on days 1 or 2 post-administration of
favipiravir. The level of susceptibility was evaluated by comparing
the difference in EC50 values between pre- and post-
administration samples. We could not analyze the viruses iso-
lated after day 3 post-administration because the virus titers in
the clinical specimens were low. EC50 values of 20 pairs of
A(H1N1)pdm09, 17 pairs of A(H3N2) and 20 pairs of B viruses are
shown in Tables 2e4, respectively. The median EC50s of the viruses
isolated pre- and 1 or 2 days post-administration were 0.99, 1.02
and 0.90 mM for A(H1N1)pdm09 (Table 2), 8.40, 14.24 and
10.97 mM for A(H3N2) (Table 3) and 3.51, 2.52 and 5.82 mM for B
(Table 4), respectively. P values between pre and post day 1 or day
2 administration were 0.25 and 0.55 for A(H1N1)pdm09, 0.36 and
0.42 for A(H3N2) and 0.30 and 0.11 for B, respectively. These re-
sults demonstrated that none of the viruses acquired statistically
signiﬁcant reduced susceptibility to favipiravir during favipiravir
administration.
The EC50 fold-change of the virus isolated post-administration
compared to the virus isolated pre-administration ranged from 0.4
to 3.3 for A(H1N1)pdm09 (Table 2), from 0.4 to 4.8 for A(H3N2)
(Table 3) and from 0.4 to 3.9 for B (Table 4), respectively. To
evaluate the signiﬁcance of slightly higher EC50 fold-changes (i.e.,
3.3e4.8-fold changes), IC50 fold-changes of the same viruses were
determined by using the plaque reduction assay. The IC50 fold-
changes of the viruses were 2.4-fold increase for A(H1N1)pdm09
showing 3.3-fold increase in EC50, 1.5-fold increase for A(H3N2)
showing 4.8-fold increase in EC50, 0.9-fold increase for B showing
3.9-fold increase in EC50 and 1.5-fold increase for B showing 3.6-
fold increase in EC50, respectively (data not shown). Since a dif-
ference in IC50 values less than 2.4-fold is clearly within experi-
mental variation, the above described results suggest that at least
4.8-fold increase in EC50 does not translate to a clinically impor-
tant difference.3.3. Comparison of RNA-dependent RNA polymerase gene
sequences of inﬂuenza viruses isolated pre- and post-administration
of favipiravir
Although none of the viruses tested exhibited reduced suscep-
tibility to favipiravir, we compared the gene sequences of the RNA-
dependent RNA polymerase subunits, PB1, PB2 and PA, of inﬂuenza
viruses isolated pre- and post-administration of favipiravir by using
Sanger sequencing. We found that two of 20 paired A(H1N1)
pdm09, one of 17 paired A(H3N2) and one of 20 paired B viruses
possessed at least one amino acid substitutions after favipiravir
administration (Table 5).
To ﬁnd increase in the substitution rates associated with favi-
piravir treatment, the frequency of these substitutions among
circulating inﬂuenza viruses was analyzed by using the Analyze
Sequence Variation (SNP) tool in the Inﬂuenza Research Database
(IRD) (Squires et al., 2012). Of 5202 PB1 sequences from A(H1N1)
pdm09 viruses, 16 (0.3%) contained V728I substitution and one
(0.02%) contained R734Q substitution. Four (0.08%) of 5301 PB2
sequences and one (0.02%) of 5369 PA sequences from A(H1N1)
pdm09 viruses contained an A221T or L666F substitution, respec-
tively. Of 5660 PA sequences from A(H3N2) viruses, 75 (1.3%)
contained a L550I substitution. None of 2000 PB2 sequences from
inﬂuenza B viruses contained an I356V substitution. Compared
with these background levels of circulating viruses, favipiravir
administration was shown to increase the mutation frequency in
the viral polymerase complex similar to a previous in vitro study
(Baranovich et al., 2013).
3.4. Polymerase activity of the A(H1N1)pdm09 virus carrying three
amino acid substitutions in the RNA-dependent RNA polymerase
subunits after favipiravir administration
An A(H1N1)pdm09 virus carried three amino acid substitutions,
V728I in the PB1, A221T in the PB2 and L666F in the PA, after
favipiravir administration, as determined by Sanger sequencing
(Table 5). Deep sequencing analysis revealed that PB1 V728I, PB2
A221Tand PA L666F substitutions of the virus were detected in 77%,
72% and 72%, respectively, of mixed populations with wild-type. To
examine the effect of these amino acid substitutions on the poly-
merase activity, a luciferase-based mini-genome assay was per-
formed. The ‘pre-favipiravir’ (i.e., wild-type) virus polymerase
complex exhibited higher luciferase activity than the ‘post-favi-
piravir’ virus polymerase complex (encoding the three mutations
listed above) (Fig. 1). The pre-favipiravir virus polymerase complex
with PB1 or PB2 of the post-favipiravir virus exhibited substantial
luciferase activity, whereas a polymerase complex of the pre-
favipiravir virus with PA of the post-favipiravir virus showed low
luciferase activity. The IC50 values of the polymerase complexes
were 46.67 mM for pre-favipiravir, 41.48 mM for PB1 V728I, 41.46 mM
for PB2 A221T, 37.62 mM for PA L666F and 19.82 mM for post-
favipiravir, respectively. These results showed that the PA L666F
substitution reduced the polymerase activity, at least in in vitro
mini-genome assay, consistent with a previous report that the PA
F666L substitution increased the polymerase activity (de Wit et al.,
2010).
3.5. NA inhibitor susceptibility of inﬂuenza viruses isolated from
patients pre- and post-administration of favipiravir
To assess the susceptibilities of inﬂuenza viruses to NA in-
hibitors after favipiravir administration, we compared the IC50
values of the viruses isolated pre- and post-administration of
favipiravir to NA inhibitors, oseltamivir and zanamivir. The IC50
values of 20 pairs of A(H1N1)pdm09, 17 pairs of A(H3N2) and 20
Table 2
Favipiravir and neuraminidase inhibitor susceptibility of inﬂuenza A(H1N1)pdm09 viruses isolated from patients pre- and post-administration of favipiravir.
Patient ID Susceptibility to:
Favipiravir (EC50 [mM])a Oseltamivir (IC50 [nM])b Zanamivir (IC50 [nM])b
Pre-treatment Day 1 or 2
post-treatment
Fold change Pre-treatment Day 1 or 2
post-treatment
Fold change Pre-treatment Day 1 or 2
post-treatment
Fold change
1 1.08 ± 0.43 3.56 ± 1.19 3.3 0.32 ± 0.08 0.24 ± 0.07 0.8 0.22 ± 0.07 0.37 ± 0.04 1.7
2 1.19 ± 0.51 1.72 ± 0.76 1.5 0.26 ± 0.07 0.18 ± 0.02 0.7 0.28 ± 0.11 0.24 ± 0.07 0.9
3 1.70 ± 1.01 1.50 ± 0.87c 0.9 0.13 ± 0.06 0.20 ± 0.06c 1.5 0.16 ± 0.06 0.34 ± 0.13c 2.1
4 2.24 ± 1.39 1.34 ± 0.69c 0.6 0.19 ± 0.004 0.23 ± 0.04c 1.2 0.26 ± 0.07 0.31 ± 0.14c 1.2
5 1.27 ± 0.24 1.18 ± 0.19 0.9 0.19 ± 0.05 0.20 ± 0.08 1.1 0.39 ± 0.07 0.26 ± 0.09 0.7
6 0.71 ± 0.41 0.82 ± 0.41c 1.2 0.16 ± 0.05 0.21 ± 0.10c 1.3 0.26 ± 0.08 0.31 ± 0.10c 1.2
7 0.94 ± 0.50 2.02 ± 1.71 2.1 0.13 ± 0.06 0.16 ± 0.08 1.2 0.25 ± 0.08 0.36 ± 0.16 1.4
8 0.39 ± 0.16 0.60 ± 0.30c 1.5 0.25 ± 0.05 0.10 ± 0.03c 0.4 0.20 ± 0.09 0.30 ± 0.04c 1.5
9 1.12 ± 0.48 0.87 ± 0.23 0.8 0.11 ± 0.05 0.16 ± 0.07 1.5 0.37 ± 0.13 0.29 ± 0.13 0.8
10 0.51 ± 0.07 1.26 ± 0.28 2.5 0.26 ± 0.09 0.17 ± 0.04 0.7 0.30 ± 0.11 0.23 ± 0.11 0.8
11 0.65 ± 0.44 0.46 ± 0.17 0.7 0.14 ± 0.06 0.11 ± 0.04 0.8 0.16 ± 0.07 0.31 ± 0.11 1.9
12 1.51 ± 0.90 0.96 ± 0.42 0.6 0.26 ± 0.10 0.19 ± 0.06 0.7 0.17 ± 0.08 0.33 ± 0.16 1.9
13 2.16 ± 0.85 0.87 ± 0.75 0.4 0.17 ± 0.07 0.22 ± 0.09 1.3 0.32 ± 0.04 0.17 ± 0.08 0.5
14 0.74 ± 0.55 0.93 ± 0.32 1.3 0.13 ± 0.02 0.25 ± 0.12 1.9 0.15 ± 0.05 0.24 ± 0.11 1.6
15 0.71 ± 0.41 0.47 ± 0.26 0.7 0.15 ± 0.07 0.11 ± 0.04 0.7 0.15 ± 0.02 0.18 ± 0.06 1.2
16 0.47 ± 0.30 0.53 ± 0.05c 1.1 0.11 ± 0.02 0.08 ± 0.04c 0.7 0.25 ± 0.11 0.28 ± 0.13c 1.1
17 0.58 ± 0.19 0.49 ± 0.20 0.8 0.21 ± 0.09 0.24 ± 0.10 1.1 0.13 ± 0.01 0.15 ± 0.04 1.2
18 0.54 ± 0.19 0.79 ± 0.53 1.5 0.26 ± 0.02 0.19 ± 0.09 0.7 0.29 ± 0.11 0.23 ± 0.08 0.8
19 1.04 ± 0.56 0.53 ± 0.24 0.5 0.25 ± 0.09 0.20 ± 0.07 0.8 0.25 ± 0.10 0.15 ± 0.04 0.6
20 2.06 ± 0.89 1.22 ± 0.71c 0.6 0.25 ± 0.12 0.13 ± 0.03c 0.5 0.35 ± 0.10 0.31 ± 0.04c 0.9
a EC50 values were determined by the use of the colorimetric cytopathic effect reduction assay. The values are presented as the mean ± SD of triplicate reactions.
b IC50 values were determined by the use of a chemiluminescent neuraminidase inhibition assay. The values are presented as the mean ± SD of triplicate reactions.
c Viruses isolated from patients on day 1 post-treatment.
Table 3
Favipiravir and neuraminidase inhibitor susceptibility of inﬂuenza A(H3N2) viruses isolated from patients pre- and post-administration of favipiravir.
Patient ID Susceptibility to:
Favipiravir (EC50 [mM])a Oseltamivir (IC50 [nM])b Zanamivir (IC50 [nM])b
Pre-treatment Day 1 or 2
post-treatment
Fold change Pre-treatment Day 1 or 2
post-treatment
Fold change Pre-treatment Day 1 or 2
post-treatment
Fold change
1 2.69 ± 1.72 6.74 ± 4.79 2.5 0.07 ± 0.02 0.13 ± 0.04 1.9 0.29 ± 0.10 0.49 ± 0.10 1.7
2 17.45 ± 10.13 14.24 ± 12.83c 0.8 0.13 ± 0.06 0.18 ± 0.03c 1.4 0.27 ± 0.10 0.24 ± 0.09c 0.9
3 18.10 ± 16.96 13.46 ± 13.17 0.7 0.16 ± 0.06 0.11 ± 0.03 0.7 0.61 ± 0.23 0.56 ± 0.16 0.9
4 5.75 ± 1.80 3.55 ± 0.86c 0.6 0.18 ± 0.05 0.07 ± 0.02c 0.4 0.81 ± 0.30 0.33 ± 0.16c 0.4
5 12.37 ± 7.17 12.43 ± 3.34 1.0 0.11 ± 0.04 0.15 ± 0.04 1.4 1.40 ± 0.45 0.68 ± 0.24 0.5
6 4.13 ± 1.93 9.51 ± 2.60 2.3 0.11 ± 0.04 0.12 ± 0.04 1.1 1.46 ± 0.39 0.57 ± 0.19 0.4
7 2.15 ± 0.72 4.37 ± 1.96 2.0 0.11 ± 0.03 0.09 ± 0.01 0.8 0.39 ± 0.08 0.73 ± 0.16 1.9
8 11.03 ± 5.29 5.35 ± 2.37c 0.5 0.10 ± 0.02 0.10 ± 0.03c 1.0 0.91 ± 0.14 0.79 ± 0.05c 0.9
9 2.16 ± 1.23 4.14 ± 2.37c 1.9 0.10 ± 0.03 0.19 ± 0.04c 1.9 0.49 ± 0.18 0.98 ± 0.06c 2.0
10 5.21 ± 3.52 25.13 ± 10.03c 4.8 0.12 ± 0.004 0.10 ± 0.01c 0.8 0.36 ± 0.06 1.06 ± 0.12c 2.9
11 20.23 ± 9.50 21.26 ± 2.29c 1.1 0.12 ± 0.06 0.12 ± 0.04c 1.0 0.50 ± 0.19 0.37 ± 0.09c 0.7
12 8.96 ± 5.42 4.03 ± 0.54c 0.4 0.08 ± 0.03 0.11 ± 0.02c 1.4 0.60 ± 0.22 0.53 ± 0.17c 0.9
13 10.12 ± 1.74 20.57 ± 5.07 2.0 0.17 ± 0.04 0.15 ± 0.05 0.9 0.79 ± 0.08 0.93 ± 0.09 1.2
14 8.40 ± 3.82 16.98 ± 2.24c 2.0 0.17 ± 0.04 0.09 ± 0.01c 0.5 0.85 ± 0.10 0.43 ± 0.15c 0.5
15 8.37 ± 4.69 12.68 ± 5.05 1.5 0.13 ± 0.02 0.13 ± 0.03 1.0 0.62 ± 0.16 0.78 ± 0.09 1.3
16 12.99 ± 3.53 5.23 ± 2.07 0.4 0.19 ± 0.02 0.06 ± 0.01 0.3 0.86 ± 0.16 0.39 ± 0.06 0.5
17 8.03 ± 2.54 16.92 ± 5.60c 2.1 0.18 ± 0.04 0.06 ± 0.02c 0.3 0.71 ± 0.09 0.46 ± 0.09c 0.6
a EC50 values were determined by the use of the colorimetric cytopathic effect reduction assay. The values are presented as the mean ± SD of triplicate reactions.
b IC50 values were determined by the use of a chemiluminescent neuraminidase inhibition assay. The values are presented as the mean ± SD of triplicate reactions.
c Viruses isolated from patients on day 1 post-treatment.
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IC50 fold-change to oseltamivir of viruses isolated before or after
treatment with favipiravir ranged from 0.4 to 1.9 for A(H1N1)
pdm09 (Table 2), from 0.3 to 1.9 for A(H3N2) (Table 3) and from 0.4
to 1.5 for B (Table 4), respectively. The IC50 fold-change to zanamivir
ranged from 0.5 to 2.1 for A(H1N1)pdm09 (Table 2), from 0.4 to 2.9
for A(H3N2) (Table 3) and from 0.4 to 2.4 for B (Table 4), respec-
tively. The median IC50 values to oseltamivir of viruses isolated pre-
and 1 or 2 days post-administration of favipiravir were 0.19, 0.17
and 0.19 mM for A(H1N1)pdm09 (Table 2), 0.12, 0.10 and 0.13 mM for
A(H3N2) (Table 3) and 2.03, 1.97 and 1.84 mM for B (Table 4),respectively. P values between pre and post day 1 or day 2
administration were 0.60 and 0.36 for A(H1N1)pdm09, 0.44 and
0.55 for A(H3N2) and 0.41 and 0.45 for B, respectively. The median
IC50s to zanamivir were 0.25, 0.31 and 0.24 mM for A(H1N1)pdm09
(Table 2), 0.62, 0.46 and 0.63 mM for A(H3N2) (Table 3) and 1.11, 0.95
and 0.99 mM for B (Table 4), respectively. P values between pre and
post day 1 or day 2 administration were 0.09 and 0.83 for A(H1N1)
pdm09, 0.81 and 0.37 for A(H3N2) and 0.31 and 0.98 for B,
respectively. These results suggest that favipiravir administration
did not affect the susceptibility of inﬂuenza viruses to NA inhibitors,
oseltamivir and zanamivir.
Table 4
Favipiravir and neuraminidase inhibitor susceptibility of inﬂuenza B viruses isolated from patients pre- and post-administration of favipiravir.
Patient ID Susceptibility to:
Favipiravir (EC50 [mM])a Oseltamivir (IC50 [nM])b Zanamivir (IC50 [nM])b
Pre-treatment Day 1 or 2
post-treatment
Fold change Pre-treatment Day 1 or 2
post-treatment
Fold change Pre-treatment Day 1 or 2
post-treatment
Fold change
1 0.69 ± 0.26 0.67 ± 0.18 1.0 2.28 ± 0.72 0.92 ± 0.43 0.4 1.13 ± 0.30 0.83 ± 0.30 0.7
2 3.92 ± 2.59 4.34 ± 2.19d 1.1 1.55 ± 0.39 0.94 ± 0.25d 0.6 0.90 ± 0.19 0.56 ± 0.25d 0.6
3c 2.79 ± 2.13 7.89 ± 7.16 2.8 3.15 ± 1.19 2.59 ± 0.46 0.8 2.46 ± 0.10 2.46 ± 0.48 1.0
4 2.60 ± 1.79 6.08 ± 4.70 2.3 1.70 ± 0.18 1.69 ± 0.79 1.0 0.50 ± 0.20 0.94 ± 0.35 1.9
5 4.99 ± 4.31 12.57 ± 3.65 2.5 1.75 ± 0.35 2.07 ± 0.23 1.2 1.14 ± 0.30 1.13 ± 0.08 1.0
6 1.21 ± 1.11 1.46 ± 0.47d 1.2 4.13 ± 0.11 3.23 ± 0.90d 0.8 3.95 ± 0.45 2.46 ± 1.13d 0.6
7 2.86 ± 1.54 2.54 ± 1.01 0.9 2.01 ± 0.48 1.87 ± 0.50 0.9 1.27 ± 0.61 1.11 ± 0.24 0.9
8 5.75 ± 3.78 2.49 ± 1.44 0.4 1.57 ± 0.55 1.73 ± 0.44 1.1 1.09 ± 0.35 2.65 ± 0.30 2.4
9 1.61 ± 1.37 2.20 ± 1.03d 1.4 1.33 ± 0.23 2.00 ± 0.08d 1.5 0.74 ± 0.34 0.75 ± 0.37d 1.0
10 0.81 ± 0.43 1.55 ± 0.77 1.9 2.02 ± 0.26 1.43 ± 0.26 0.7 1.51 ± 0.32 1.20 ± 0.44 0.8
11 8.68 ± 8.30 5.82 ± 4.32 0.7 2.06 ± 0.76 1.92 ± 0.56 0.9 0.65 ± 0.25 0.66 ± 0.23 1.0
12 8.17 ± 4.64 12.03 ± 5.67 1.5 2.03 ± 0.56 1.84 ± 0.44 0.9 0.71 ± 0.07 0.60 ± 0.09 0.8
13 0.71 ± 0.29 2.80 ± 1.04 3.9 1.08 ± 0.33 1.57 ± 0.20 1.5 1.22 ± 0.43 0.52 ± 0.12 0.4
14 5.96 ± 4.89 8.04 ± 4.92 1.3 1.83 ± 0.38 1.71 ± 0.42 0.9 0.68 ± 0.11 0.64 ± 0.12 0.9
15 4.13 ± 3.56 4.12 ± 2.09 1.0 2.11 ± 0.32 2.20 ± 0.60 1.0 0.75 ± 0.13 0.73 ± 0.08 1.0
16 5.23 ± 1.71 7.05 ± 2.01 1.3 3.45 ± 0.98 4.21 ± 0.48 1.2 2.69 ± 1.11 2.50 ± 0.88 0.9
17 4.71 ± 3.29 3.41 ± 2.45 0.7 2.48 ± 0.40 2.31 ± 0.50 0.9 0.98 ± 0.07 0.99 ± 0.11 1.0
18 3.10 ± 2.64 2.52 ± 0.91d 0.8 2.19 ± 0.23 1.97 ± 0.44d 0.9 1.04 ± 0.10 0.95 ± 0.06d 0.9
19 1.54 ± 1.12 5.55 ± 1.38d 3.6 2.07 ± 0.28 1.92 ± 0.22d 0.9 1.15 ± 0.13 1.34 ± 0.10d 1.2
20 9.33 ± 2.64 9.74 ± 5.87 1.0 1.81 ± 0.46 1.79 ± 0.14 1.0 1.31 ± 0.48 1.08 ± 0.32 0.8
a EC50 values were determined by the use of the colorimetric cytopathic effect reduction assay. The values are presented as the mean ± SD of triplicate reactions.
b IC50 values were determined by the use of a chemiluminescent neuraminidase inhibition assay. The values are presented as the mean ± SD of triplicate reactions.
c B/Yamagata-lineage virus.
d Viruses isolated from patients on day 1 post-treatment.
Table 5
Amino acid substitutions in the RNA-dependent RNA polymerase subunits of
inﬂuenza viruses detected after favipiravir administration.
Subtype No. of patients tested Patient ID Amino acid substitution ina
PB1 PB2 PA
A(H1N1)pdm09 20 1 V728I A221T L666F
12 R734Q eb e
A(H3N2) 17 9 e e L550I
B 20 12 e I356V e
a Amino acid position numbering is A subtype and B type speciﬁc.
b Not detected.
Fig. 1. Polymerase activities of the A(H1N1)pdm09 viral polymerase complex carrying
amino acid substitutions in the RNA-dependent RNA polymerase subunits. Mini-
genome assays were performed by transfecting 293T cells with protein expression
plasmids (PB1, PB2, PA and NP), pPolINP(0)luc2(0) for the production of vRNA encoding
a ﬁreﬂy luciferase gene, and pRL-null renilla luciferase control reporter vector. At 24 h
posttransfection, cells were assayed for luciferase activity. The relative ﬁreﬂy luciferase
activities, normalized to the renilla luciferase activities, are shown. Error bars indicate
the standard deviations from three independent experiments in triplicates.
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In Japan, favipiravir has been approved for inﬂuenza pandemic
preparedness. Here, we conducted a CPE reduction assay to eval-
uate the favipiravir susceptibility of inﬂuenza viruses for antiviral
susceptibility surveillance. The susceptibility of the viruses to
favipiravir was expressed as the EC50. Since these values are assay-
speciﬁc, they cannot be compared with results published by others
(Smee et al., 2001). However, our data from the CPE reduction assay,
together with the conventional plaque reduction assay, that viruses
resistant to NA inhibitors are sensitive to favipiravir match those
published by Sleeman et al. (2010). These results suggest that the
CPE reduction assay is an option to screen inﬂuenza viruses for
susceptibility to favipiravir.
Inﬂuenza A(H1N1) or A(H1N1)pdm09 viruses with reduced
susceptibility to favipiravir have not been detected even after
sequential passages in MDCK cells in the presence of favipiravir
(Baranovich et al., 2013; Daikoku et al., 2014; Sangawa et al., 2013).
We examined the favipiravir susceptibility of 57 pairs of inﬂuenza
A(H1N1)pdm09, A(H3N2) and B viruses isolated from patients pre-
and post-administration of favipiravir enrolled in its clinical trials
and found no viruses with statistically signiﬁcant reduced suscep-
tibility to favipiravir after its administration. These results supportthe possibility that mutation(s) causing resistance to favipiravir is
fatal for inﬂuenza virus replication as previously described
(Baranovich et al., 2013; Daikoku et al., 2014).
A previous report suggested that favipiravir increases the mu-
tation frequency in the inﬂuenza viral genome beyond the biolog-
ical tolerance threshold (Baranovich et al., 2013). In this study, two
of 20 paired A(H1N1)pdm09, one of 17 paired A(H3N2) and one of
20 paired B viruses possessed at least one amino acid substitutions
in the RNA-dependent RNA polymerase subunits, PB1, PB2 or PA,
after favipiravir administration (Table 5). In a previous study,
several amino acid substitutions in the PB1, PB2 or PA of inﬂuenza
E. Takashita et al. / Antiviral Research 132 (2016) 170e177176A/PR/8/34(H1N1) virus were also detected during sequential pas-
sages in MDCK cells in the presence of favipiravir (Daikoku et al.,
2014), but they were no identical substitutions with this study.
These amino acid substitutions did not affect susceptibilities of the
viruses to favipiravir.
After favipiravir treatment, an A(H1N1)pdm09 virus possessed
three amino acid substitutions, PB1 V728I, PB2 A221Tand PA L666F.
In vitro mini-genome assay showed that the PA L666F substitution
reduced the polymerase activity, consistent with a previous study
of an A(H7N7) virus (de Wit et al., 2010). The L666 is located in the
C-terminal domain of PA and makes hydrophobic contact with PB1
(He et al., 2008; Obayashi et al., 2008). Mutation of residue L666
disrupts the binding to PB1 and the synthesis of vRNA, cRNA and
mRNA (He et al., 2008; Obayashi et al., 2008). Thus, the PA L666F
substitution might cause similar disruptions, resulting in reduced
polymerase activity.
Susceptibility of inﬂuenza A(H1N1) and A(H1N1)pdm09 viruses
to NA inhibitors, oseltamivir and zanamivir, was not altered by
serial passage in MDCK cells with or without favipiravir
(Baranovich et al., 2013). To assess susceptibility of inﬂuenza
A(H1N1)pdm09, A(H3N2) and B viruses to oseltamivir and zana-
mivir after favipiravir administration, we compared IC50s of 57 pairs
of inﬂuenza A(H1N1)pdm09, A(H3N2) and B viruses isolated from
patients pre- and post-administration of favipiravir. None of these
viruses displayed reduced susceptibility to NA inhibitors, suggest-
ing that favipiravir administration did not alter NA inhibitor sus-
ceptibility of inﬂuenza viruses.
We previously reported that 55 of 516 inﬂuenza A(H1N1)pdm09
viruses isolated from patients prophylactically or therapeutically
treated with oseltamivir showed resistance to oseltamivir (Ujike
et al., 2011). Six of 55 oseltamivir-resistant A(H1N1)pdm09 vi-
ruses were detected by 2 days post-administration of oseltamivir
(Ujike et al., 2011). In contrast, we found no favipiravir-resistant
viruses at least by 2 days post-administration of favipiravir.
Therefore, the frequency of emergence of antiviral-resistant viruses
in clinical settings is most likely much lower for favipiravir
compared with that for oseltamivir.
In summary, we conducted a CPE reduction assay to evaluate the
susceptibility of inﬂuenza viruses to a novel antiviral drug, favi-
piravir. The assay will be an option to monitor the favipiravir sus-
ceptibility of inﬂuenza viruses. Favipiravir administration for 1 or 2
days (1200/400 mg for 1 day þ 400 mg bid during the following
day) did not affect the susceptibility of inﬂuenza A(H1N1)pdm09,
A(H3N2) and B viruses to favipiravir and NA inhibitors.
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